MeSH D007010 - hyponatremia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Alkem Laboratories | Tolvaptan | Tolvaptan |  | 2020-05-19 |  |  |
| Apotex | Tolvaptan | Tolvaptan |  | 2020-05-19 |  |  |
| Hetero | Tolvaptan | Tolvaptan |  | 2021-07-16 |  |  |
| Endo | Tolvaptan | Tolvaptan |  | 2022-02-15 |  |  |
| Cumberland Pharmaceuticals | Conivaptan | Vaprisol |  | 2005-12-29 | $-0.147 M | Q4/22-Q1/24 |
| Otsuka | Tolvaptan | Jinarc |  | 2015-05-27 |  |  |
| Tolvaptan | Jynarque | 2026-09-01 | 2018-04-23 |  |  | |
| Tolvaptan | Samsca | 2026-09-01 | 2009-05-19 |  |  | |
| MSN Laboratories | Tolvaptan | Tolvaptan |  | 2023-06-21 |  |  |
| Accord Healthcare | Tolvaptan | Tolvaptan Accord |  |  |  |  |
| Lupin Research | Tolvaptan | Tolvaptan |  | 2025-04-23 |  |  |
| Rising Pharmaceuticals | Polyethylene glycol 3350, Tezacitabine, Sodium chloride, Sodium bicarbonate | Peg 3350 Electrolytes |  | 2010-01-28 |  |  |
| Polyethylene glycol 3350, Sodium chloride, Sodium bicarbonate | Peg, Potassium Chloride, Bicarbonate, |  | 2010-04-02 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
100%4/4
Phase 3
40%6/15
Approved: 2Overall Success rate: 40%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use